VEGFA and adrenal cortex carcinoma: Cabozantinib, which inhibits multiple kinases including VEGF, AXL, c-MET, and RET, demonstrated promising efficacy in a phase 2 trial with an overall survival of 16 weeks in advanced ACC patients, suggesting it may be a viable option following failure of other treatments (47).